Invest in the weight loss drug revolution and beyond
$HRTS ETF
Learn more

MNTL
Neuroscience and Mental Health ETF

Investing in the future of cognitive health and science

Why MNTL ETF?

icons-themes-mntl-unmet-medical-need 3
Unmet medical need

1 billion people worldwide suffer from CNS diseases. Many illnesses have limited disease modifying treatments and are a huge economic burden on healthcare systems.

Source: WHO
icons-themes-hrts-innovation
Innovation

An innovation wave is rising with the watershed launch of the first medicines for Alzheimer’s to breakthroughs in gene editing, non-opioid pain, and targeted treatments for depression.

icons-themes-hrts-research
Research expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations.

icons-themes-mntl-growing-mkt 1
Growing Market

The outsized economic burden of these diseases means a large and fast-growing addressable market with high payer acceptance according to Tema’s research.

icons-themes-oncology-uncorrelated
Uncorrelated

Performance of many companies relies on clinical or commercial success, which is an uncorrelated source of return.

Fund Overview

Fund Details

As of April 23, 2024
Primary Exchange
Nasdaq
Ticker
MNTL
AuM (USD)
$10,624,574
# of Holdings
47
Fund Inception Date
01/22/24
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
Implied Liquidity (# of shares)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
3,963,512
Implied Liquidity (USD)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
$96M
Shares Outstanding
440,000
Investment Advisor
Tema Global Limited
Sub-Investment Advisor
NEOS Investments, LLC
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/30/2025.

Fund Summary

The actively managed Tema Neuroscience and Mental Health ETF seeks to provide long-term growth of capital by investing in companies tackling diseases of the central nervous system and mental health. We have reached a watershed moment in innovation with the approval of the first disease modifying agent in Alzheimer’s with significant innovation following in neuropsychology and genetic neurological disorders. 
The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.

Portfolio Manager

David K. Song, MD, PhD, CFA
Investment Partner
David K. Song, MD, PhD, CFA
David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.

How does the Tema MNTL ETF fit in a portfolio?

Investment Style Box

Frame 48095809

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM
Ellipse 625

MNTL ETF

Ellipse 625

Equity core

Where could a position be funded from?

  • Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.

  • Provides a balanced exposure across key technologies and company risk profiles.

  • Could replace a satellite position or a growth-oriented alpha driver.

Portfolio Breakdown

Top 10 holdings

As of April 23, 2024
Company
% of Nav
ELI LILLY & CO.
4.94%
VERTEX PHARMACEUTICALS, INC.
4.84%
NEUROCRINE BIOSCIENCES, INC.
4.68%
REGENERON PHARMACEUTICALS, INC.
4.51%
STRYKER CORP.
3.88%
BIOGEN, INC.
3.85%
DEXCOM, INC.
3.83%
ARGENX SE
3.67%
DENALI THERAPEUTICS, INC.
3.28%
CRINETICS PHARMACEUTICALS, INC.
3.24%

Country Breakdown

United States
75.85%
Ireland
7.10%
Netherlands
3.67%
Belgium
3.02%
Others
10.36%

Industry Breakdown

Healthcare
98.18%
Cash & Cash Equivalents
1.78%
NA
0.03%
  • Performance
  • Distributions
  • Premium / Discount

Prices & Performance

As of
Mar 31, 2024

MNTL

3 months

1 Year

3 Years

5 Years

Since inception

NAV
2.84% 2.84%
Market Price
3.10% 3.10%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.


The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

ST Cap Gains

0.19 0.18 0.16 0.15 0.2 0.16 0.15 0.12 0.14 0.23 0.15 0.19 0.18 0.11 0.18 0.18 0.22

Premium/Discount

Сhart Table

MNTL NAV / Market Price

NAV$24.15
NAV change (1D)$0.30
Median Bid/Ask Spread (30 Day)0.35%
Market Price$24.19
Market Price Change (1D)$0.31
Premium/Discount0.19%
As of: April 23, 2024

How to buy

*Neither Tema Global Limited nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.